Stock Events

Twist Bioscience 

€36.08
132
+€2.76+8.28% Today

Statistics

Day High
36.08
Day Low
36.06
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
2.05B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.47
-1.21
-0.95
-0.7
Expected EPS
-0.696245
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0ME.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Twist Bioscience's synthetic DNA products.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers long-read sequencing technologies, competing with Twist Bioscience in the genomics and DNA sequencing market.
Agenus
AGEN
Mkt Cap111.1M
Agenus is involved in immuno-oncology, a field that relies on synthetic biology and genomics, areas where Twist Bioscience operates.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is focused on gene editing, a sector that directly competes with Twist Bioscience's synthetic DNA for research and therapeutic applications.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the gene editing space, competing with Twist Bioscience in the development of genomic tools and therapies.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing with Twist Bioscience in the genomic medicine field.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, areas where Twist Bioscience's synthetic DNA products are relevant.
Adaptive Biotechnologies
ADPT
Mkt Cap693.12M
Adaptive Biotechnologies is engaged in the immune-driven medicine space, leveraging genomics and competing with Twist Bioscience in the use of synthetic DNA for immune system understanding.
Bionano Genomics
BNGO
Mkt Cap42.14M
Bionano Genomics provides tools for genomic analysis, competing in the broader genomics market where Twist Bioscience offers synthetic DNA solutions.

About

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Emily Marine Leproust Ph.D.
Employees
919
Country
US
ISIN
US90184D1000
WKN
000A2N7L2

Listings